Heike Geschwindner
Research Subjects
Research Interests
Heike Geschwindner has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Gabriela Bieri-Brüning
Geriatric Service and Nursing Homes of the City of Zurich, 8050 Zurich, Switzerland
2 shared publications - Albert Wettstein
Center for Gerontology, University of Zurich, Pestalozzistrasse 24, 8032, Zurich, Switzerland
1 shared publication - Andreas Hüni
Department of Aging Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
1 shared publication - Caroline Moor
Center for Gerontology, University of Zurich, Pestalozzistrasse 24, 8032, Zurich, Switzerland
1 shared publication - Christoph Hock
Institute for Regenerative Medicine, University of Zurich , Switzerland
1 shared publication - Florian Riese
Healthy Longevity Center, University of Zurich, Stampfenbachstrasse 73, 8006, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 6 March 2023
- Published by MDPI AG in Geriatrics
- Vol. 8 (2) , 35
Feasibility of a 12-Month Follow-Up in Swiss Older Adults after Post-Acute Care in Nursing Homes—A Pilot Study
(1) Background: Post-acute care (PAC) aims to support functional recovery in older adults after acute hospitalization in order to regain a sufficient level of self-care facilitating their return home. However, the long-term outcomes of PAC are understudied due to challenges in recording a follow-up. We aimed to investigate the feasibility of a 12-month follow-up after PAC in Swiss nursing homes, examining practicability and potential factors influencing participation rate. (2) Methods: Collection of one-year follow-up data among 140 eligible patients after PAC in nursing homes was attempted. Patients were recruited using letters and phone calls between August and December 2017. We compared baseline data of all initial PAC patients with those who declined participation in the follow-up to identify factors potentially influencing participation. (3) Results: Overall mortality at 12 months was 25% (n = 35 of 140). Of the 105 survivors, 53 (50%) refused participation, 26 (25%) were interviewed, and 26 (25%) were lost to follow-up. Comparison of baseline characteristics between participants and objectors indicated significant statistical differences in Mini-Mental State Examination (MMSE) scores (participants mean of 26.0 [SD 3.92] vs. objectors mean of 23.5 points [SD 4.40], p = 0.015). Further, logistic regression showed statistically significantly greater odds of participation (OR 1.25 [95% CI 1.06–1.48]) for each point increase in MMSE scores. (4) Conclusions: Long-term follow-up studies in older adults after PAC are challenging due to high mortality and dropout rates. Of note, intact cognitive function at baseline was associated with a higher willingness to participate in a follow-up phone interview. The assessment of cognitive function should be considered when estimating the participation rate in older patients.
- 6 March 2023
- Published by MDPI AG in Geriatrics
- Vol. 8 (2) , 35
Open AccessFeasibility of a 12-Month Follow-Up in Swiss Older Adults after Post-Acute Care in Nursing Homes—A Pilot Study
(1) Background: Post-acute care (PAC) aims to support functional recovery in older adults after acute hospitalization in order to regain a sufficient level of self-care facilitating their return home. However, the long-term outcomes of PAC are understudied due to challenges in recording a follow-up. We aimed to investigate the feasibility of a 12-month follow-up after PAC in Swiss nursing homes, examining practicability and potential factors influencing participation rate. (2) Methods: Collection of one-year follow-up data among 140 eligible patients after PAC in nursing homes was attempted. Patients were recruited using letters and phone calls between August and December 2017. We compared baseline data of all initial PAC patients with those who declined participation in the follow-up to identify factors potentially influencing participation. (3) Results: Overall mortality at 12 months was 25% (n = 35 of 140). Of the 105 survivors, 53 (50%) refused participation, 26 (25%) were interviewed, and 26 (25%) were lost to follow-up. Comparison of baseline characteristics between participants and objectors indicated significant statistical differences in Mini-Mental State Examination (MMSE) scores (participants mean of 26.0 [SD 3.92] vs. objectors mean of 23.5 points [SD 4.40], p = 0.015). Further, logistic regression showed statistically significantly greater odds of participation (OR 1.25 [95% CI 1.06–1.48]) for each point increase in MMSE scores. (4) Conclusions: Long-term follow-up studies in older adults after PAC are challenging due to high mortality and dropout rates. Of note, intact cognitive function at baseline was associated with a higher willingness to participate in a follow-up phone interview. The assessment of cognitive function should be considered when estimating the participation rate in older patients.
- Open Access
- 30 October 2022
- Published by Wiley in Advanced Science
- Vol. 9 (35) , e2204774
On‐Site Quantification and Infection Risk Assessment of Airborne SARS‐CoV‐2 Virus Via a Nanoplasmonic Bioaerosol Sensing System in Healthcare Settings
On‐site quantification and early‐stage infection risk assessment of airborne severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high spatiotemporal resolution is a promising approach for mitigating the spread of coronavirus disease 2019 (COVID‐19) pandemic and informing life‐saving decisions. Here, a condensation (hygroscopic growth)‐assisted bioaerosol collection and plasmonic photothermal sensing (CAPS) system for on‐site quantitative risk analysis of SARS‐CoV‐2 virus‐laden aerosols is presented. The CAPS system provided rapid thermoplasmonic biosensing results after an aerosol‐to‐hydrosol sampling process in COVID‐19‐related environments including a hospital and a nursing home. The detection limit reached 0.25 copies/µL in the complex aerosol background without further purification. More importantly, the CAPS system enabled direct measurement of the SARS‐CoV‐2 virus exposures with high spatiotemporal resolution. Measurement and feedback of the results to healthcare workers and patients via a QR‐code are completed within two hours. Based on a dose‐responseµ model, it is used the plasmonic biosensing signal to calculate probabilities of SARS‐CoV‐2 infection risk and estimate maximum exposure durations to an acceptable risk threshold in different environmental settings.
- 30 October 2022
- Published by Wiley in Advanced Science
- Vol. 9 (35) , e2204774
Open AccessOn‐Site Quantification and Infection Risk Assessment of Airborne SARS‐CoV‐2 Virus Via a Nanoplasmonic Bioaerosol Sensing System in Healthcare Settings
On‐site quantification and early‐stage infection risk assessment of airborne severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high spatiotemporal resolution is a promising approach for mitigating the spread of coronavirus disease 2019 (COVID‐19) pandemic and informing life‐saving decisions. Here, a condensation (hygroscopic growth)‐assisted bioaerosol collection and plasmonic photothermal sensing (CAPS) system for on‐site quantitative risk analysis of SARS‐CoV‐2 virus‐laden aerosols is presented. The CAPS system provided rapid thermoplasmonic biosensing results after an aerosol‐to‐hydrosol sampling process in COVID‐19‐related environments including a hospital and a nursing home. The detection limit reached 0.25 copies/µL in the complex aerosol background without further purification. More importantly, the CAPS system enabled direct measurement of the SARS‐CoV‐2 virus exposures with high spatiotemporal resolution. Measurement and feedback of the results to healthcare workers and patients via a QR‐code are completed within two hours. Based on a dose‐responseµ model, it is used the plasmonic biosensing signal to calculate probabilities of SARS‐CoV‐2 infection risk and estimate maximum exposure durations to an acceptable risk threshold in different environmental settings.
- Open Access
- 24 August 2016
- Published by Springer Nature in BMC Palliative Care
- Vol. 15 (1) , 1-8
The last phase of life with dementia in Swiss nursing homes: the study protocol of the longitudinal and prospective ZULIDAD study
The proportion of older people with advanced dementia who will die in nursing homes is constantly growing. However, little is known about the dying phase, the type of symptoms, the management of symptoms and the quality of life and dying in people with advanced dementia. The ZULIDAD (Zurich Life and Death with Advanced Dementia) study aims at extending the current scientific knowledge by providing first data from Switzerland. The ZULIDAD study employs a prospective design to study nursing home residents with advanced dementia for three years or until their death in eleven nursing homes in Zurich. Observational data from quarterly questionnaires for relatives and primary nurses is combined with data from the Resident Assessment Instrument – Minimum Data Set (RAI-MDS). Special focus is put on 1) the cross-sectional analysis of baseline and post-mortem data regarding quality of life and quality of dying and how the perceptions of these measures differ between relatives and primary nurses, 2) the longitudinal analyses of established health outcome measures (e.g., EOLD, MSSE, BISAD, QUALID) in order to understand their trajectories and 3) international comparisons of cross-sectional and longitudinal data. The ZULIDAD study is one of the few existing prospective studies on end-of-life care in dementia and it is the first prospective study to describe the situation in Switzerland. Its multi-perspective approach allows a comprehensive approximation to central health outcome measures at the end of life such as pain, suffering or quality of life. Providing insights into the current provision of care, it can serve as a basis for improving dementia end-of-life care in Switzerland and internationally.
- 24 August 2016
- Published by Springer Nature in BMC Palliative Care
- Vol. 15 (1) , 1-8
Open AccessThe last phase of life with dementia in Swiss nursing homes: the study protocol of the longitudinal and prospective ZULIDAD study
The proportion of older people with advanced dementia who will die in nursing homes is constantly growing. However, little is known about the dying phase, the type of symptoms, the management of symptoms and the quality of life and dying in people with advanced dementia. The ZULIDAD (Zurich Life and Death with Advanced Dementia) study aims at extending the current scientific knowledge by providing first data from Switzerland. The ZULIDAD study employs a prospective design to study nursing home residents with advanced dementia for three years or until their death in eleven nursing homes in Zurich. Observational data from quarterly questionnaires for relatives and primary nurses is combined with data from the Resident Assessment Instrument – Minimum Data Set (RAI-MDS). Special focus is put on 1) the cross-sectional analysis of baseline and post-mortem data regarding quality of life and quality of dying and how the perceptions of these measures differ between relatives and primary nurses, 2) the longitudinal analyses of established health outcome measures (e.g., EOLD, MSSE, BISAD, QUALID) in order to understand their trajectories and 3) international comparisons of cross-sectional and longitudinal data. The ZULIDAD study is one of the few existing prospective studies on end-of-life care in dementia and it is the first prospective study to describe the situation in Switzerland. Its multi-perspective approach allows a comprehensive approximation to central health outcome measures at the end of life such as pain, suffering or quality of life. Providing insights into the current provision of care, it can serve as a basis for improving dementia end-of-life care in Switzerland and internationally.